142 related articles for article (PubMed ID: 29551446)
21. Stem cell transplantation for lymphoma patients with HIV infection.
Michieli M; Mazzucato M; Tirelli U; De Paoli P
Cell Transplant; 2011; 20(3):351-70. PubMed ID: 20875226
[TBL] [Abstract][Full Text] [Related]
22. Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation.
Moreb JS; Byrne M; Shugarman I; Zou F; Xiong S; May WS; Norkin M; Hiemenz J; Brown R; Cogle C; Wingard JR; Hsu JW
J Clin Apher; 2018 Feb; 33(1):29-37. PubMed ID: 28556233
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Qiao W; Zhao J; Wang C; Wang T; Xing Y
Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
[TBL] [Abstract][Full Text] [Related]
24. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
[TBL] [Abstract][Full Text] [Related]
25. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.
Peniket AJ; Ruiz de Elvira MC; Taghipour G; Cordonnier C; Gluckman E; de Witte T; Santini G; Blaise D; Greinix H; Ferrant A; Cornelissen J; Schmitz N; Goldstone AH;
Bone Marrow Transplant; 2003 Apr; 31(8):667-78. PubMed ID: 12692607
[TBL] [Abstract][Full Text] [Related]
26. What is the role of autologous transplant for lymphoma in the current era?
Stiff P
Hematology Am Soc Hematol Educ Program; 2015; 2015():74-81. PubMed ID: 26637704
[TBL] [Abstract][Full Text] [Related]
27. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission.
Vose JM; Rizzo DJ; Tao-Wu J; Armitage JO; Bashey A; Burns LJ; Christiansen NP; Freytes CO; Gale RP; Gibson J; Giralt SA; Herzig RH; Lemaistre CF; McCarthy PL; Nimer SD; Petersen FB; Schenkein DP; Wiernik PH; Wiley JM; Loberiza FR; Lazarus HM; van Biesen K; Horowitz MM
Biol Blood Marrow Transplant; 2004 Feb; 10(2):116-27. PubMed ID: 14750077
[TBL] [Abstract][Full Text] [Related]
28. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
[TBL] [Abstract][Full Text] [Related]
29. Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma.
Shin HJ; Kim K; Lee JW; Song MK; Lee JJ; Lee HS; Lee WS; Kim SJ; Chung JS
Eur J Haematol; 2014 Nov; 93(5):414-21. PubMed ID: 24813053
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients.
Krejci M; Buchler T; Hajek R; Svobodnik A; Krivanova A; Pour L; Adam Z; Mayer J; Vorlicek J
Bone Marrow Transplant; 2005 Jan; 35(2):159-64. PubMed ID: 15543200
[TBL] [Abstract][Full Text] [Related]
31. Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma.
Kansagra A; Gonsalves WI; Gertz MA; Buadi FK; Dingli D; Dispenzieri A; Lacy MQ; Hayman SR; Kapoor P; Muchtar E; Kourelis TV; Warsame R; Leung N; Zeldenrust SR; Lust JA; Rajkumar SV; Kyle RA; Hogan W; Kumar SK
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2127-2132. PubMed ID: 29656139
[TBL] [Abstract][Full Text] [Related]
32. Beta-2 microglobulin predicts the outcome after autologous stem cell transplantation in non-Hodgkin lymphoma.
Atesoglu EB; Hacıhanefioglu A; Gulbas Z
Transfus Apher Sci; 2015 Feb; 52(1):65-71. PubMed ID: 25577449
[TBL] [Abstract][Full Text] [Related]
33. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.
Yoon DH; Sohn BS; Jang G; Kim EK; Kang BW; Kim C; Kim JE; Kim S; Lee DH; Lee JS; Park SJ; Park CJ; Huh J; Suh C
Transfusion; 2009 Sep; 49(9):1890-900. PubMed ID: 19453991
[TBL] [Abstract][Full Text] [Related]
34. Adverse impact of delay of platelet recovery after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma and multiple myeloma.
Okada Y; Kimura F; Kurita N; Takahashi H; Shimazu Y; Mizuno S; Uchida N; Kataoka K; Hiramoto N; Ota S; Kako S; Tsukada N; Kanda Y; Kurahashi S; Doki N; Nishikawa A; Kim SW; Hangaishi A; Kanda J; Fukuda T; Atsuta Y; Kondo E; Kawamura K; Nakasone H
Cytotherapy; 2023 Nov; 25(11):1212-1219. PubMed ID: 37354150
[TBL] [Abstract][Full Text] [Related]
35. Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age.
McCarthy PL; Hahn T; Hassebroek A; Bredeson C; Gajewski J; Hale G; Isola L; Lazarus HM; Lee SJ; Lemaistre CF; Loberiza F; Maziarz RT; Rizzo JD; Joffe S; Parsons S; Majhail NS
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1116-23. PubMed ID: 23660172
[TBL] [Abstract][Full Text] [Related]
36. High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Leuk Lymphoma; 2006 Aug; 47(8):1545-52. PubMed ID: 16966265
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of Older Adults with Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation: A Mayo Clinic Cohort Analysis.
Wudhikarn K; Johnson BM; Inwards DJ; Porrata LF; Micallef IN; Ansell SM; Hogan WJ; Paludo J; Villasboas JC; Johnston PB
Transplant Cell Ther; 2023 Mar; 29(3):176.e1-176.e8. PubMed ID: 36563788
[TBL] [Abstract][Full Text] [Related]
38. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation.
Gordan LN; Sugrue MW; Lynch JW; Williams KD; Khan SA; Wingard JR; Moreb JS
Leuk Lymphoma; 2003 May; 44(5):815-20. PubMed ID: 12802919
[TBL] [Abstract][Full Text] [Related]
39. [Autologous stem cell transplantation in haematological disorders,1980-2002].
Beckers MM; Verdonck LF; Cornelissen JJ; Schattenberg AV; Janssen JJ; Willemze R; van Imhoff GW; van der Lelie JH; Wijermans P; Schaafsma R; Baars J; van Marwijk Kooij MR; Biesma DH; van Biezen A; Brand R; Schouten HC
Ned Tijdschr Geneeskd; 2010; 154():A2025. PubMed ID: 20977803
[TBL] [Abstract][Full Text] [Related]
40. Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma.
Garderet L; Iacobelli S; Koster L; Goldschmidt H; Johansson JE; Bourhis JH; Krejci M; Leleu X; Potter M; Blaise D; Koenecke C; Peschel C; Radocha J; Metzner B; Lenain P; Schäfer-Eckart K; Pohlreich D; Grasso M; Caillot D; Einsele H; Ladetto M; Schönland S; Kröger N
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1372-1378. PubMed ID: 29408334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
